Neuramis Lidocaine — SHAPE HA Filler for Nasolabial Folds & Lip Enhancement

Neuramis Lidocaine is Medytox’s standard-density HA filler — 20 mg/mL cross-linked HA + 0.3% lidocaine via patented SHAPE Technology (Stabilized Hyaluronic Acid Particle Engineering). 92% cross-linking efficiency with residual BDDE under 0.4 ppm. Engineered for mid-dermal placement targeting nasolabial folds, lip enhancement, and moderate wrinkles.

Neuramis Lidocaine Dermal Filler is manufactured by Medytox Inc., a South Korea-based medical device and pharmaceutical company established in 2000. The product is part of the Neuramis dermal filler range, which is distributed across multiple international markets. Regulatory status: KFDA registered · CE marked · FDA DMF · ISO 13485 · EDQM certified.

Neuramis Lidocaine Dermal Filler contains 20 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Medytox Inc.’s SHAPE Technology (Stabilized Hyaluronic Acid Particle Engineering) technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per Medytox Inc.’s clinical data, Neuramis Lidocaine Dermal Filler delivers Up to 9 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Mid dermis placement typically delivers the longer end of the duration range.

Neuramis Lidocaine Dermal Filler is engineered for mid dermis placement. The standard recommended needle is 27G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Neuramis Lidocaine Dermal Filler regulatory status: KFDA registered · CE marked · FDA DMF · ISO 13485 · EDQM certified. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Neuramis Lidocaine Dermal Filler between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Neuramis Lidocaine Dermal Filler uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Neuramis Lidocaine Dermal Filler can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

SHAPE (Stabilized Hyaluronic Acid Particle Engineering) is Medytox’s proprietary two-step cross-linking process used across the Neuramis range. The technology produces monophasic HA gel with 92% cross-linking efficiency — meaning more HA molecules are bound to BDDE during the cross-linking reaction, reducing residual BDDE to under 0.4 ppm (well below international safety thresholds). The result: a stable, cohesive gel with high purity, minimal post-injection inflammation risk, and sustained 9-month durability.